ライフサイエンスコーパス: treated group

1 njugate was added to one of the HMP systems (treated group).

2 ster and higher than the 20% in the siBmAce1-treated group.

3 Quality of life was worse for the treated group.

4 hypoperfusion was reduced in the cilostazol-treated group.

5 treated group and 40 children in the placebo-treated group.

6 s markers was also increased in the ketamine-treated group.

7 -0.62 to -0.05, p = 0.02) versus the insulin-treated group.

8 d to the recipients; and (iii) recipient ALA-treated group.

9 9 +/- 2.40 and 0.14 +/- 0.11 in the non-CA4P-treated group.

10 th stretch were similar to the non-TGF-beta1-treated group.

11 nated from the study sooner than either drug treated group.

12 4 h, whereas 6 of 9 rats survived in the DHA-treated group.

13 n-treated group compared with the FIV(+)/PBS-treated group.

14 ve reinnervation, compared with the dressing-treated group.

15 vascular density was also reduced in the C4-treated group.

16 educed I/R injury as compared to the vehicle-treated group.

17 e prognosis in this bortezomib-dexamethasone-treated group.

18 al: 1.24-11.67, P = .0194) in the tamsulosin-treated group.

19 rable to or better than those of the vaccine-treated group.

20 -treated group compared with the IgG control-treated group.

21 p, and 0.91 (95% CI, 0.43-1.95) for the CPAP-treated group.

22 bacteria compared with BAL from the placebo-treated group.

23 art rate during exercise than in the placebo-treated group.

24 tment group and 82% (9/11) in the prednisone-treated group.

25 4 +/- 6%; p<0.05) compared to control premiR treated group.

26 ia, shoulder dystocia, and macrosomia in the treated group.

27 in PBM-treated animals compared to the sham-treated group.

28 s hook use was similar in the two tamsulosin treated group.

29 r mothers, versus only 25% in the antibiotic-treated group.

30 CD8(+) T cells) was observed in the anti-B7h-treated group.

31 7, 10, 14, and 21 days than the DOX-beta-TCP-treated group.

32 hers to infants (p=0.03) than the antibiotic-treated group.

33 he IAP treated group compared to the vehicle treated group.

34 significantly elevated in high PAH/high PFAS treated group.

35 V6 (all P < .05) and V8 (all P < .05) in LPP-treated group.

36 roup, and no alterations were greater in the treated group.

37 e sham group and 2 of 48 persons (4%) in the treated group.

38 cell protease-1 (MCPT-1) in the microneedles treated group.

39 ldren across all communities) in the placebo-treated group.

40 ted group compared with those in the placebo-treated group.

41 octurnal acrophase compared to the medically treated group.

42 ipocalin (NGAL) was lower (P = 0.031) in the treated group.

43 therapy but not compared with the tacrolimus-treated group.

44 esistance remained lower (P < 0.0001) in the treated group.

45 of better synaptic function in the inhibitor-treated group.

46 f a CD19(-) cell population in the rituximab-treated group.

47 was observed in LPP-treated but not placebo-treated group.

48 also were significantly lower in the CD47mAb-treated groups.

49 gag and in gp41-CD in both the PI- and NNRTI-treated groups.

50 er were similar in the sirolimus and vehicle treated groups.

51 exhibit statistical difference from the non-treated groups.

52 ence of protection from immune attack in the treated groups.

53 in every region were almost similar in both treated groups.

54 d complete remission was observed in the aFP-treated groups.

55 of CD8+ T cells to Treg increased in the aFP-treated groups.

56 ta-cells compared with corresponding vehicle-treated groups.

57 bserved after 10 months of treatment in both treated groups.

58 between sirolimus-treated and non-sirolimus-treated groups.

59 scular flow were compared between ultrasound-treated groups.

60 ignificantly (p < 0.05) reduced in the xenon-treated groups.

61 e tolerance between roflumilast- and placebo-treated groups.

62 There was no bone loss in any treated groups.

63 ce rate between the surgically and medically treated groups.

64 (n = 14), SCIT- (n = 10), and SLIT- (n = 8) treated groups.

65 piratory failure in either of the surfactant-treated groups.

66 ely to be 20/40 or better in the ranibizumab-treated groups.

67 ilar in the rivaroxaban-treated and warfarin-treated groups.

68 p<0.05) compared to respective control siRNA treated groups.

69 eated groups (CP-P+CYC) versus the CYC alone-treated groups.

70 ia, granuloma, or collagen deposition in the treated groups.

71 ly altered between the control and ibuprofen-treated groups.

72 higher in these groups than in staurosporine-treated groups.

73 nce was demonstrated between the placebo and treated groups.

74 identified miRNAs were downregulated in heat-treated groups.

75 as observed in empty MSs and single-drug MSs treated groups.

76 sia, was markedly attenuated in both saporin-treated groups.

77 for high PAH/low PFAS and low PAH/high PFAS treated groups.

78 nfirmed ME cases were observed in fingolimod-treated groups (0.5 mg: n = 4, 0.3%; 1.25 mg: n = 15, 1.

79 nction (p < 0.05) were observed in the xenon-treated group, 1 month after trauma.

80 e Shannon's alpha-diversity was lower in the treated group (10.60; 95% CI, 8.82-12.36) than the place

81 % lower Salmonella carriage is measured in a treated group, 14 days post-Salmonella challenge.

82 In 289 patients in the as-treated group (151 the HM3 and 138 the HMII), survival f

83 INA control group was similar for the MARINA treated group (+17.6 letters) and the FRB-MARINA cohort

84 survival for the overall cohort (hypothermia-treated group, 17.0% [246 of 1443 patients]; non-hypothe

85 number of SAEs per patient was higher in the treated group (2.7 versus 1.3; P = 0.003).

86 olyp scores after 16 weeks in the omalizumab-treated group (-2.67, P = .001), which was confirmed by

87 7.0% [246 of 1443 patients]; non-hypothermia-treated group, 20.5% [725 of 3529 patients]; RR, 0.79 [9

88 1 +/- 10 mg/dL) in comparison to the vehicle-treated group (238 +/- 11 mg/dL).

89 ere significantly increased (p<0.001) in the treated group (25.84+/-1.41%) compared with the control

90 In the treated group, 25(OH)D(total) rose from 18 +/- 7 to 43 +

91 ated for 4 wk (mean change in both sorafenib-treated groups, -38.4%; range, +9.1% to -79.4%).

92 y) than in the respective IL-22-high placebo-treated group (39.6% and 56.3% at 4 and 12 weeks) or the

93 ix days (8.8 +/- 0.4) compared to the saline-treated group (6.1 +/- 0.3; P < 0.001) without a change

94 In the previously treated group, 70% of the patients were able to proceed

95 hs in the FAi-treated compared with the sham-treated group (73.8% vs. 23.8% of eyes, respectively).

96 s of any grade were higher in the duloxetine-treated group (78% v 50%); rates of grade 3 adverse even

97 seen with fezakinumab in the IL-22-high drug-treated group (82.8% and 139.4% at 4 and 12 weeks, respe

98 ated tumors grew significantly slower in aFP-treated groups (aFP and aFP + anti-PD-1 groups) and comp

99 erior epithelial length when compared to EMD-treated groups after 3 months.

100 In clodronate-liposome-treated group, allograft hearts exhibited preserved tiss

101 PTX-solution treated group also developed severe metastatic lesions a

102 DFO-treated groups also had evidence of reduced dermal thick

103 and VF parameters tended to be worse in the treated group, although without statistical significance

104 .2-1.5; 11 of 3633 patients) in the edoxaban-treated group and 0.4% (0.2-1.7; 14 of 3594) in the warf

105 .2-0.5; 11 of 3633 patients) in the edoxaban-treated group and 0.7% (0.4-1.0; 24 of 3594 patients) in

106 5.63 +/- 3.09 and 1.68 +/- 0.77 in the CA4P-treated group and 1.29 +/- 2.40 and 0.14 +/- 0.11 in the

107 artile range, 14 to 25) in the intravenously treated group and 17 days (interquartile range, 14 to 25

108 For vitamin E, there were 197 cases in the treated group and 192 in the placebo group (hazard ratio

109 One eye in the treated group and 2 eyes in the control group had an IOP

110 rvival time, double that of the DOX liposome-treated group and 3.4-fold greater than that of the untr

111 3-4.6; 143 of 3633 patients) in the edoxaban-treated group and 4.1% (3.5-4.8; 147 of 3594 patients) i

112 -60 months were analyzed in the azithromycin-treated group and 40 children in the placebo-treated gro

113 across all communities) in the azithromycin-treated group and 6.7% (95% CI 4.0%-12.6%; 36 of 542 chi

114 rgery-related complications was 8.61% in the treated group and 8% in the control group (not significa

115 oduct Statistics, we identified a dabigatran-treated group and a 1:2 propensity-matched warfarin-trea

116 h DMO was euro777.09 +/- 49.45 for the laser treated group and euro7153.62 +/- 212.15 for the anti-VE

117 sthenia developed in 8 of 76 patients in the treated group and in 15 of 82 patients in the nonimmunot

118 in 24 patients (12.1%) in the intravenously treated group and in 18 (9.0%) in the orally treated gro

119 were 1239 (7.2%) incident CVD events in the treated groups and 2361 (13.8%) events in the control gr

120 ces in CAIX expression between the sorafenib-treated groups and the nontreated patients.

121 genes were found common to both 1,25(OH)2D3-treated groups and were composed of genes previously lin

122 ROP and treatment with laser or cryotherapy (treated group) and those with regressed ROP who had not

123 a1-blockers before cataract surgery were the treated group, and age-, sex-, and year of surgery-match

124 de (GLP)-1 levels as compared to the placebo-treated group, and also that type 2 diabetic patients tr

125 larization scores in 0.4% and 2.0% ripasudil-treated groups, and mRNA levels of angiogenic and pro-in

126 ) in the hippocampus and striatum of vehicle-treated group as compared to sham-operated rats.

127 GSH contents increased 44% in treated group as compared to the injury group.

128 cyte culture supernatants of the microneedle treated group as compared to untreated group, suggesting

129 s was significantly lower in the simvastatin-treated group, as was the urine albumin-creatinine ratio

130 and its effects were compared with a saline-treated group at five different time points of reperfusi

131 all communities) than it was in the placebo-treated group at month 12 (mean 15.3%, 95% CI 10.8%-20.6

132 s, parasitemia was lower in the azithromycin-treated group at month 12 (mean prevalence 8.8%, 95% CI

133 h) were specifically enriched (>3%) in UV-4B-treated groups at passage five.

134 In both sorafenib-treated groups, baseline and posttreatment tumor targeti

135 treated group and in 18 (9.0%) in the orally treated group (between-group difference, 3.1 percentage

136 s 1.2% (0.9-1.6; 51 of 4122) in the warfarin-treated group; between greater than 3 months and 6 month

137 pression and vessel density in the sorafenib-treated groups but no differences in CAIX expression bet

138 of PDGF-BB and VEGF were higher in the PRGF-treated group, but differences were not significant.

139 Functional outcome in 3K3A-APC-treated group, but not in vehicle-treated group, correla

140 rease of acute tubular injury in the CD47mAb-treated group compared to control.

141 PSA, and total cholesterol in the isoflavone-treated group compared to men receiving placebo were not

142 he crush, more neurons survived in the rtACS-treated group compared to sham-treated controls.

143 Tlr4, and Lyz genes was observed in the IAP treated group compared to the vehicle treated group.

144 ission rates were 48% lower in the exebacase-treated group compared with antibiotics alone.CONCLUSION

145 counts were consistently found in the saline-treated group compared with chlorhexidine (P = 0.03).

146 as lower at the end of NP (P = 0.017) in the treated group compared with control kidneys.

147 days after injections was 24% longer in ADF-treated group compared with controls (488 +/- 120 versus

148 -term corneal allograft survival in the IL-2 treated group compared with controls.

149 III IFNs in the airways (for the fluticasone-treated group compared with controls: mean IFNbeta BAL p

150 to -5.1) in the therapeutic plasma exchange-treated group compared with no change with no therapeuti

151 were significantly decreased in the CD47mAb-treated group compared with the control group.

152 ippocampus were higher in the FIV(+)/insulin-treated group compared with the FIV(+)/PBS-treated group

153 s model was significantly reduced in the mAb-treated group compared with the IgG control-treated grou

154 e pollen season (-53.7%, P = .03) in the LPP-treated group compared with those in the placebo-treated

155 ER and PR were reduced in EC313-treated groups compared to controls (p < 0.001) and UPA

156 cell density was significantly lower in ABX treated groups compared to controls.

157 were significantly higher in antidepressant-treated groups compared to those with controls.

158 ntifying responders and nonresponders in the treated groups compared with MR elastography (23 of 26,

159 for threat information was decreased in the treated group, compared with the waiting group, the day

160 ents in the placebo plus pemetrexed-platinum-treated group completed at least one PRO assessment.

161 nt (ADC) measured by DW-MRI increased in the treated group consistent with cytotoxic edema.

162 sitive, whereas only 5.1% in the doxycycline-treated group contained bacteria.

163 n 3K3A-APC-treated group, but not in vehicle-treated group, correlated inversely with the reductions

164 amin E and C levels were high in combination-treated groups (CP-P+CYC) versus the CYC alone-treated g

165 sham group was 45% greater than that of the treated group (decrease, 15.81+/-8.93 dB; P = 0.07).

166 ficant compared with that of the nonbiologic treated group (DeltaLRNC, -0.22 mm(2) versus 0.14 mm(2),

167 The ACE inhibitor-treated group demonstrated a significant reduction in sy

168 in periocular inflammation, the radiotherapy-treated group demonstrated a significantly greater impro

169 The ketamine-treated group displayed bladder hyperactivity and decrea

170 Surviving rats in the DHA-treated group displayed moderately improved hemodynamics

171 myogenic differentiation in pre-culture SBB-treated groups do not exhibit statistical difference fro

172 Only the UC-MSC-treated group exhibited significant improvements in left

173 The tumors in the mP-PTX treated group grew more slowly than those treated with s

174 n the intention-to-treat analysis, the CLEAR-treated group had a mean (SD) decrease in lesion diamete

175 After 12 wk, the treated group had a significantly better total SPPB scor

176 Patients in the treated group had a significantly thinner choroidal thic

177 gn of brain function whereas rats in the DHA-treated group had recurrent seizures and spontaneous res

178 Histologically the CD47mAb-treated group had significantly reduced scores of acute

179 The GEM/DOX liposome-treated group had the longest median survival time, doub

180 However, MyMRKO and EPL-treated groups had a 35% reduction in serum cystatin-C l

181 AgNS and AgNC treated groups had select reductions in gut microbiota r

182 Over the follow-up, both surfactant-treated groups had significantly better pulmonary outcom

183 val in the PGD3-cohort was 71.4%, the C1-INH-treated-group had a one-year-survival of 82.5%, the cont

184 closure group versus 10.2% in the medically treated group; hazard ratio, 0.64; 95% confidence interv

185 In the treated groups, hearts were perfused with ranolazine or

186 l infiltration, which were improved in the 3 treated groups; however, the combined group presented th

187 .4-1.0; 24 of 3594 patients) in the warfarin-treated group (HR 0.45, 95% CI 0.22-0.92).

188 d 0.4% (0.2-1.7; 14 of 3594) in the warfarin-treated group (HR 0.78, 95% CI 0.36-1.72).

189 5-4.8; 147 of 3594 patients) in the warfarin-treated group (HR 0.97, 95% CI 0.77-1.22); cumulative in

190 were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06-1.87; p = 0.017).

191 1).day(-1)) in the supplied water (infarcted treated group, I + PY).

192 = 1.5; adjusted P <= 0.1) were identified in treated group in comparison to control.

193 multinucleated cells were observed in the EA-treated group in relation to group EP.

194 e comparable between anti-IL-15- and control-treated groups in both cohorts.

195 differences between bortezomib- and placebo-treated groups in median measured GFR at 24 months (33 v

196 ere significantly (p < 0.05) better in xenon-treated groups in the early phase (24 hr) and up to 4 da

197 ascular events remained consistent in the TO-treated groups in the PCI and CABG arms.

198 Treated groups in the trial were very similar on most ba

199 ogical examination of the lenses in the NACA-treated group indicated that NACA was able to reverse th

200 -PGC-1alpha was decreased in the resveratrol-treated group, indicating a higher level of activation,

201 on-targets was significantly enhanced in the treated group, indicating memantine-associated improveme

202 ut microbiome was significantly lower in the treated group (inverse Simpson's alpha-diversity, 5.03;

203 s was 100 (41) mV eq, while in the medically treated group it was 131 (69) mV eq (difference: P = .01

204 s was significantly higher in antidepressant-treated groups (k = 6, OR = 0.55, 95% CI = 0.35 to 0.86,

205 In the metformin-treated group, Ki-67 was 12.9% lower at hysterectomy tha

206 symptoms of infectious disease while the Pn treated group looked healthy.

207 ntly higher percentage of eyes in the stable treated group maintained VA of >= 6/12 (55.1% vs. 24.2%)

208 nderwent an appendectomy (the "Appendectomy" treated group), matching them 5:1 to 274,980 controls, e

209 er in the FAi-treated compared with the sham-treated group (mean 1.7 vs. 5.3, respectively, P < 0.001

210 In the as-treated group (n = 124), clinical (P = .003) and radiolo

211 icantly higher (P = .001) in the canakinumab-treated group (n = 5 of 7) than in the placebo group (n

212 ction in probe accumulation in the docetaxel treated group (n = 5, p < .05).

213 In the as-treated group, natalizumab continuers received natalizum

214 In the vehicle-treated groups, no significant change in TBR, K1, K1/k2,

215 group and a 1:2 propensity-matched warfarin-treated group of 4,978 and 8,936, respectively.

216 7 and 16 postinfection in the immunocomplex-treated group of infected mice.

217 ll numbers in corneas from the immunocomplex-treated group of mice.

218 outcome in our study is comparable to the IA-treated group of the MR CLEAN trial and better than the

219 Two orthodontically treated groups of 35 patients each, with (Cort) and with

220 d control group, and both 2-hour and 24-hour treated groups of 4T1 cells were used in this study.

221 We treated groups of animals with 1 dose of VSV-EBOV either

222 nalyses were undertaken in the TO and non-TO treated groups of both study arms.

223 We treated groups of nude mice bearing 7-d-old SW1222 xenog

224 .04) 3 months after PTRA in the elamipretide-treated group only.

225 in adverse events between the NR and placebo-treated groups or between groups at different NR doses.

226 rs post-MCAO with either 1 mg/kg PNU-120596 (treated group) or vehicle only (untreated group).

227 ed in the sirolimus-treated vs non-sirolimus-treated groups overall (26 of 97 [26.8%] vs 89 of 232 [3

228 01), with humanized germ-free and antibiotic-treated groups overlapping in beta-diversity.

229 Within the ICS-treated groups, OW and NW children had similar asthma sy

230 hen compared with baseline in the antibiotic-treated group (P < 0.05), but presented higher values th

231 % CI, 1.9-14.9) higher than the voriconazole-treated group (P = .01).

232 ed a longer survival time in the favipiravir-treated group (P = .015).

233 than study participants in the voriconazole-treated group (P = .046).

234 an increase of 0.07 (3.2) mm in the placebo-treated group (P = .05).

235 (-13.9 words per minute) with no loss in the treated group (P = 0.02).

236 interquartile range, 14 to 25) in the orally treated group (P=0.48).

237 1000 patient-years (95% CI 19.2-21.5) in the treated groups (P < .0001).

238 ue thickness gain was significant only in CM-treated groups (P <0.05).

239 up did not improve in either groups (p = 0.8 treated group, p = 0.1 control group).

240 e found by either quadrant analysis (p = 0.1 treated group, p = 0.5 control group) or MD analysis (p

241 0.5 control group) or MD analysis (p = 0.2, treated group, p = 0.9 control group).

242 Both strontium ranelate-treated groups presented higher staining of OPN and BSP

243 dication scores improved in both Bet v 1 COP-treated groups, reaching statistical significance over p

244 I 12.5-25% compared with the vehicle control treated group, respectively.

245 -octreotate group, and the (177)Lu-DOTA-JR11-treated group, respectively.

246 for ALT and AST, in Vit D, LE and LE + Vit D treated groups, respectively).

247 Los and Tel treated group resulted in the 5.33 and 14.33 fold increa

248 The DOX-beta-TCP + EDTA-treated group retained more DOX during the periods of 3,

249 HS-treated groups revealed persistent scar tissue for 10 we

250 tacle-corrected visual acuity, the natamycin-treated group scored 8.4 points (95% CI, 1.9-14.9) highe

251 und that study participants in the natamycin-treated group scored, on average, 4.3 points (95% CI, 0.

252 At 21 days, the DOX-beta-TCP + EDTA-treated group showed a 194.7 microg/mL value.

253 Overall, FIR-treated group showed a higher DPPH radical scavenging ac

254 ontrol group, corneas from the immunocomplex-treated group showed a significant reduction in the amou

255 The prednisone-treated group showed an adjusted mean 6.4-point (95% CI,

256 r mouse model, MDB5 containing nanoparticles treated group showed significant inhibition of tumor gro

257 The ozone-treated group showed significantly higher quality of lif

258 Concurrently, the treated group showed visible lesions, a higher FDG uptak

259 The EMD-treated groups showed a superior length of NC [4.13 +/-

260 In the dermis and subcutaneous fat, the EVE treated groups showed significant increases in blood ves

261 abolic tissues tested in vehicle- or BRD3308-treated groups showed virtually no sign of immune cell i

262 opine and control groups, with both atropine-treated groups showing significant myopic retardation co

263 Compared with the placebo and rBet v 1-treated groups, SLIT with rMal d 1 reduced rMal d 1-indu

264 a control group (CG; n = 60) and a meloxicam-treated group (TG; n = 60) that received either a single

265 s were less pronounced in hearts in the cell-treated group than in MI hearts (P<0.05), and these impr

266 icantly less muscle fiber injury in the PJ34-treated group than in the Lactated Ringer-treated mice a

267 ore was 1.2 points higher in the simvastatin-treated group than in the placebo group (95% CI 0.2-2.3)

268 t) were all significantly higher in the NACA-treated group than in the sodium selenite-induced catara

269 at 80 MPa after vitrification-warming in the treated groups than controls.

270 amylase activity was significantly higher in treated groups than in controls.

271 activity was significantly lower in the PJ34-treated groups than in the Lactated Ringer group at 7 an

272 Bats in one vaccine-treated group, that received raccoon poxviruses (RCN) ex

273 Relative to the VKA-treated group, the associated risk of MI was significant

274 In contrast to the vehicle-treated group, the hippocampus of animals receiving RESV

275 one revealed that, compared with the vehicle-treated group, the PTH-treated WT mice had reduced trabe

276 s showed increases especially at the 100% N2-treated group, the total FAAs statistically differed wit

277 Further, in Tel and Los treated groups, the TGF-beta1 active levels were signifi

278 appeared least at end of storage for 100% N2 treated-group, the latter having decreased melanosis sco

279 2 in the moderate- and high-intensity statin-treated groups; the LDL-C reductions at week 12 were com

280 Ai-treated group when compared with the sham-treated group underwent IOP-lowering surgery (5.7% vs. 1

281 ipants who were receiving ART (the infected, treated group) underwent flow cytometry of endothelial c

282 ention of cognitive decline in the inhibitor-treated group using novel object recognition (NOR) and f

283 .8-1.4; 44 of 4118 patients) in the edoxaban-treated group versus 1.2% (0.9-1.6; 51 of 4122) in the w

284 alysis indicated 0% of HBsAg+ infants in the treated group versus 2.84% in the NTx group (P=0.002).

285 ce [CI]: 0.6-3.8) of HBsAg+ infants from the treated group versus 7.6% (95% CI: 4.9-10.3) in the NTx

286 acebo; 78% DHA); the mean DHA intake for the treated group was 469 mg/d.

287 Severe TV observed in the non-treated group was associated with increased protein oxid

288 Survival in the CT-1-treated group was higher than in the untreated group and

289 No change in the placebo-treated group was observed.

290 The treated group was older (median 62 yr treated pooled vs

291 uramine-induced serotonin/prolactin in the T-treated group was significantly higher than the other gr

292 st, the mean microleakage value of the CPNE7-treated group was significantly lower than that of the c

293 Viral RNA from the HCV sshRNA-treated groups was altered in sequences complementary to

294 If feasible, patients in the orally treated group were discharged to outpatient treatment.

295 d approximately half as many eyes in the FAi-treated group when compared with the sham-treated group

296 rease in ETDRS letters was higher in the PDT-treated group when comparing baseline and first evaluati

297 ol group, but not in the NF-kappaB inhibitor-treated groups, whereas TAT levels were elevated in all

298 obtained in the adhesive tissues of the APC-treated group, which correlated with significantly reduc

299 f treatment weighting to create DES- and BMS-treated groups whose observed baseline characteristics w

300 when compared to chronic mono- and combined-treated groups, without affecting GLP-1 receptor, prepro

301 ): OVX plus saline solution; zoledronic acid-treated group (ZOL) (n = 6): OVX plus ZOL; SHAM (n = 4):